ТАУБ Ребекка (US),БРОТЦ Тильманн (US),ФРЭНК Джон (US),КОЭН Ларри (US),ПАТЕЛ Хеманткумар Х. (US),ЧЕМБУРКАР Санджай Р. (US),СОВИК Дэвид П. (US)
申请号：
RU2013108908/15
公开号：
RU2013108908A
申请日:
2011.07.25
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. Composition containing the R- and S-enantiomers of N- [3- [5 - [(4-fluorophenyl) methyl] -2-thienyl] -1-methyl-2-propynyl] -N-hydroxyurea or its pharmaceutically effective salts wherein said composition contains less than 2% S-enantiomer. 2. A composition according to claim 1, characterized in that said composition contains less than 1% S-enantiomer. The composition according to claim 1, characterized in that the composition consists of the R- and S-enantiomers of N- [3- [5 - [(4-fluorophenyl) methyl] -2-thienyl] -1-methyl-2-propinyl] -N-hydroxyurea or its pharmaceutically effective salts. 4. The composition according to claim 3, characterized in that said composition consists of less than 1% S-enantiomer. The composition according to claim 1, characterized in that the composition is provided in the form of a unit dosage form for oral administration, and the composition is present in an amount of about 25-100 mg. A composition according to claim 5, characterized in that said composition is present in an amount of about 25, 50, 75 or 100 mg. A composition according to claim 5, characterized in that said composition is present in an amount of about 100 mg. The composition according to claim 5, characterized in that the unit dosage form for oral administration is a tablet or capsule. The use of a composition according to claim 1 for treating a pathology associated with leukotrienes in a subject in need thereof. The use of claim 9, wherein said subject is a human. The use according to claim 9, characterized in that the pathology is a heart attack, stroke, peripheral artery disease, cardiovascular disease, inflammatory disease, cancer, induction1. Композиция, содержащая R- и S-энантиомеры N-[3-[5-[(4-фторфенил)метил]-2-тиенил]-1-метил-2-пропинил]-N-гидроксимочевины или ее фармацевтически эффективных солей, при этом указанная композиция содержит менее 2% S-энантиомера.2. Композиция по п.1, отличающаяся тем, что указанная композиция содержит менее 1% S-энантиомера.3. Ко
